Table 5.
Comparison of average model-predicted risks with observed risks of histologically-aggressive prostate cancer in an initial prostate biopsy among subgroups of the PCPT validation cohort.
| Risk of Histologically-aggressive Prostate Cancer |
||||
|---|---|---|---|---|
| Group | Number of Patients |
Mean Model- Predicted Risk (%) |
Observed Percentage of Patients |
AUC (95% CI) |
| All | 3833 | 12.0 | 8.5 | .78 (.75–.80) |
| Age <65 yr | 808 | 10.4 | 8.5 | .79 (.74–.84) |
| Age ≥65 yr | 3025 | 12.4 | 8.4 | .77 (.75–.80) |
| Caucasian | 3720 | 12.0 | 8.2 | .77 (.74–.80) |
| Non-Caucasian | 113 | 13.7 | 16.8 | .85 (.75–.94) |
| BMI < 30 kg/m2 | 2827 | 11.4 | 8.4 | .77 (.74–.80) |
| BMI ≥ 30 kg/m2 | 1006 | 13.8 | 8.6 | .80 (.75–.85) |
| No family history | 3226 | 10.3 | 7.8 | .79 (.75–.82) |
| Family history | 607 | 21.2 | 11.9 | .73 (.67–.80) |
| Normal DRE | 3628 | 10.9 | 7.6 | .77 (.74–.80) |
| Abnormal DRE | 205 | 31.9 | 24.4 | .65 (.56–.73) |
| PSA density <0.102 ng/mL/cc | 3518 | 9.3 | 6.5 | .74 (.70–.77) |
| PSA density ≥0.102 ng/mL/cc | 315 | 42.7 | 30.8 | .58 (.51–.65) |